MCID: BRN015
MIFTS: 50

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 12 15
Bronchioloalveolar Carcinoma 12 17
Minimally Invasive Lung Adenocarcinoma 12
Adenocarcinoma, Bronchiolo-Alveolar 45
Bronchioloalveolar Adenocarcinoma 74
Bronchioalveolar Lung Carcinoma 12
Carcinoma Bronchioloalveolar 56

Classifications:



External Ids:

Disease Ontology 12 DOID:4926
MeSH 45 D002282
NCIt 51 C2923
SNOMED-CT 69 36310008
UMLS 74 C0007120

Summaries for Bronchiolo-Alveolar Adenocarcinoma

Disease Ontology : 12 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary : Bronchiolo-Alveolar Adenocarcinoma, also known as bronchioloalveolar carcinoma, is related to mucinous bronchioloalveolar adenocarcinoma and in situ pulmonary adenocarcinoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Gefitinib and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and heart, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 mucinous bronchioloalveolar adenocarcinoma 32.1 CDX2 KRT20 KRT7 NKX2-1
2 in situ pulmonary adenocarcinoma 31.9 ASPH EGFR HYAL2
3 sclerosing hemangioma 30.3 KRT7 NKX2-1
4 adenocarcinoma 30.3 CDH1 EGFR KRAS MUC4
5 papillary adenocarcinoma 30.2 CDH1 KRT7 NKX2-1
6 solid adenocarcinoma with mucin production 30.1 KRT7 MUC6 NKX2-1
7 small cell cancer of the lung 30.1 EGFR KRT20 KRT7 NKX2-1
8 adenocarcinoma in situ 29.7 CDX2 KRAS KRT20 KRT7
9 thyroid cancer 29.6 CDH1 EGFR KRAS NKX2-1
10 mucinous adenocarcinoma 29.2 CDX2 EGFR KRAS KRT20 KRT7 NKX2-1
11 lung cancer 28.7 CDH1 EGFR FHIT KRAS KRT20 KRT7
12 lung cancer susceptibility 3 28.4 CDH1 CDX2 EGFR FHIT KRAS KRT20
13 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.5
14 nonmucinous bronchioloalveolar adenocarcinoma 11.5
15 acneiform dermatitis 10.4 EGFR KRAS
16 basaloid squamous cell carcinoma 10.4 EGFR KRT7
17 atypical choroid plexus papilloma 10.4 KRT7 NKX2-1
18 rete testis neoplasm 10.4 KRT20 NKX2-1
19 paget disease, extramammary 10.4 KRT20 KRT7
20 immune system organ benign neoplasm 10.4 KRT20 KRT7
21 eccrine sweat gland neoplasm 10.4 KRT20 KRT7
22 thymus lipoma 10.4 KRT20 KRT7
23 dermoid cyst 10.4 KRT20 KRT7
24 mucinous cystadenocarcinoma 10.4 KRT20 KRT7
25 cystadenofibroma 10.4 KRT20 KRT7
26 pancreatic mucinous cystadenoma 10.4 KRT20 KRT7
27 benign breast adenomyoepithelioma 10.4 EGFR KRT7
28 paronychia 10.3 EGFR KRAS
29 pneumonia 10.3
30 oncocytic breast carcinoma 10.3 EGFR KRT7
31 lipid-rich carcinoma 10.3 CDH1 EGFR
32 inflammatory breast carcinoma 10.3 CDH1 EGFR
33 ovarian germ cell teratoma 10.3 KRT7 NKX2-1
34 ovarian germ cell cancer 10.3 KRT7 NKX2-1
35 cystic basal cell carcinoma 10.3 KRT20 KRT7
36 seminal vesicle adenocarcinoma 10.3 KRT20 KRT7
37 transverse colon cancer 10.3 KRT20 KRT7
38 malignant syringoma 10.3 KRT20 KRT7
39 papillary adenoma 10.3 KRT7 NKX2-1
40 colloid adenoma 10.3 KRT20 NKX2-1
41 breast myoepithelial neoplasm 10.3 CDH1 KRT7
42 superior mesenteric artery syndrome 10.3 CDX2 MUC6
43 papillary transitional carcinoma 10.3 KRT20 KRT7
44 eyelid carcinoma 10.3 KRT20 KRT7
45 krukenberg carcinoma 10.3 KRT20 KRT7
46 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
47 lung adenoid cystic carcinoma 10.3 KRAS NKX2-1
48 intratubular embryonal carcinoma 10.3 KRT20 KRT7
49 vulval paget's disease 10.2 KRT20 KRT7
50 mucinous adenofibroma 10.2 CDX2 KRT7

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


fever, dyspnea, hemoptysis, coughing

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 ASPH CDH1 CDX2 EGFR FHIT KRAS
2 homeostasis/metabolism MP:0005376 9.61 ASPH CDH1 CDX2 EGFR FHIT HYAL2
3 neoplasm MP:0002006 9.17 ASPH CDH1 CDX2 EGFR FHIT KRAS

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 38904 10339178 498142
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
7
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
9
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
10
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
13
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
16
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
17 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
18 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
19 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
21 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Antiviral Agents Phase 3,Phase 2,Phase 1
26 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
27 Immunoglobulins Phase 2, Phase 3,Phase 1
28 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
29 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
30 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
31 Antibodies Phase 2, Phase 3,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Etoposide phosphate Phase 3,Phase 2,Phase 1
34 Mitogens Phase 3,Phase 2
35 Epoetin alfa Phase 3 113427-24-0
36 Hematinics Phase 3,Phase 2
37 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
38 Folate Phase 3,Phase 2,Phase 1
39 Vitamin B9 Phase 3,Phase 2,Phase 1
40 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
41 Vitamin B Complex Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
43
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
44
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
45
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
46
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
47
Promethazine Approved, Investigational Phase 2 60-87-7 4927
48
Topotecan Approved, Investigational Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
49
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
50
Lomustine Approved, Investigational Phase 2 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
6 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
7 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
8 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
9 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
17 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
18 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
19 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
20 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
21 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
22 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
23 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
24 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
25 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
26 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
27 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
28 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
29 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
30 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
31 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
32 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
33 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
34 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
35 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
36 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
37 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
38 Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00425646 Phase 2 imatinib mesylate
39 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
40 Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
41 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride
42 Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
43 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00117962 Phase 2 carboplatin;pemetrexed disodium
44 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
45 Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00081302 Phase 2 carboplatin;paclitaxel
46 Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed NCT00033553 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
47 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
48 Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
49 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin
50 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed NCT00346320 Phase 2

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

MalaCards organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

42
Lung, Brain, Heart, Testes, Endothelial, Lymph Node, Thyroid

Publications for Bronchiolo-Alveolar Adenocarcinoma

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

(show top 50) (show all 274)
# Title Authors Year
1
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. ( 28801183 )
2018
2
Image Diagnosis: Bronchioloalveolar Carcinoma Presenting as Unilateral "Crazy-Paving" Pattern on High-Resolution Computed Tomography. ( 27083012 )
2016
3
Case report of the bronchioloalveolar carcinoma. ( 25709995 )
2015
4
The Demise of the Term Bronchioloalveolar Carcinoma. ( 26230592 )
2015
5
Bronchioloalveolar carcinoma: time for a new term. ( 24012240 )
2014
6
Congenital cystic adenomatoid malformation with associated mucinous bronchioloalveolar carcinoma in a neonate. ( 24093545 )
2014
7
Bronchioloalveolar carcinoma in a juvenile rhadomyosarcoma patient. ( 24570868 )
2014
8
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma. ( 24747679 )
2014
9
Significance of the histological and ultrastructural features of elastic fibers in diagnosis of bronchioloalveolar carcinoma. ( 24867516 )
2014
10
Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. ( 25654480 )
2014
11
Global gene expression differentiating pure bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar carcinoma features. ( 22864788 )
2013
12
Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis. ( 23286648 )
2013
13
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. ( 23415808 )
2013
14
Bronchioloalveolar carcinoma in a young patient: a case report. ( 23490086 )
2013
15
Well-differentiated adenocarcinoma-bronchioloalveolar carcinoma-in situ adenocarcinoma: a conundrum. ( 23939151 )
2013
16
Clinical characteristics of patients with bronchioloalveolar carcinoma: a retrospective study of 44 cases. ( 23992004 )
2013
17
Former mucinous bronchioloalveolar carcinoma revisited. ( 24369471 )
2013
18
Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene? ( 22296236 )
2012
19
Severe bronchorrhea in a patient with bronchioloalveolar carcinoma. ( 22315118 )
2012
20
Aspects of bronchioloalveolar carcinoma and of adenocarcinoma with a bronchioloalveolar component: CT findings. ( 22576431 )
2012
21
Bilateral lung transplant for bronchioloalveolar carcinoma: first case in China. ( 22758387 )
2012
22
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial. ( 22767177 )
2012
23
A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. ( 22842620 )
2012
24
Positron emission tomography in bronchioloalveolar carcinoma of the lung. ( 23017426 )
2012
25
Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case-control studies in the International Lung Cancer Consortium (ILCCO). ( 21072579 )
2011
26
Dramatic response to pemetrexed in a patient with pneumonic-type mucinous bronchioloalveolar carcinoma. ( 21252722 )
2011
27
Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity. ( 21317746 )
2011
28
Micronodular pattern caused by bronchioloalveolar carcinoma. ( 21419558 )
2011
29
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). ( 21422434 )
2011
30
Bronchioloalveolar carcinoma. ( 21500124 )
2011
31
Bronchorrhea in bronchioloalveolar carcinoma. ( 21555870 )
2011
32
Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-I): case-control study results. ( 21587123 )
2011
33
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). ( 21716143 )
2011
34
Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor. ( 21911454 )
2011
35
How many adenocarcinoma lung cancers come from bronchioloalveolar carcinoma? ( 27755811 )
2011
36
Solitary nodular pure bronchioloalveolar carcinoma. ( 19147987 )
2010
37
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. ( 19581016 )
2010
38
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. ( 20085869 )
2010
39
Mucinous and nonmucinous bronchioloalveolar carcinoma and smoking. ( 20093246 )
2010
40
Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. ( 20138387 )
2010
41
Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings. ( 20512541 )
2010
42
Sclerosing variant of the bronchioloalveolar carcinoma: imaging findings in an atypical case. ( 20589217 )
2010
43
Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. ( 20592627 )
2010
44
The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. ( 20614257 )
2010
45
Bronchioloalveolar carcinoma and the significance of invasion: predicting biologic behavior. ( 20923299 )
2010
46
Surgical resection for patients with mucinous bronchioloalveolar carcinoma. ( 21029945 )
2010
47
Cytodiagnostic aspects of bronchioloalveolar carcinoma manifesting with small cell morphology on respiratory specimens: a case report. ( 21053590 )
2010
48
Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target? ( 21138169 )
2010
49
Bronchioloalveolar carcinoma: a translational perspective. ( 21138171 )
2010
50
Bronchioloalveolar Carcinoma and Minimally Invasive Adenocarcinoma. ( 26839025 )
2010

Variations for Bronchiolo-Alveolar Adenocarcinoma

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

9 (show top 50) (show all 13410)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 0
2 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 0
3 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 0
4 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 0
5 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 0
6 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 0
7 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 0
8 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 0
9 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 0
10 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 0
11 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 0
12 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 0
13 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 0
14 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 0
15 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 0
16 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 0
17 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 0
18 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 0
19 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 0
20 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 0
21 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 0
22 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 0
23 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 0
24 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 0
25 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 0
26 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 0
27 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 0
28 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 0
29 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 0
30 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 0
31 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 0
32 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 0
33 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 0
34 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 0
35 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 0
36 COSM6982440 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 0
37 COSM6983995 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7133C>G p.T2378S 16:72795549-72795549 0
38 COSM6978013 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1855C>G p.H619D 16:72958291-72958291 0
39 COSM6962938 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4181C>A p.S1394* 16:72798501-72798501 0
40 COSM6937443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 0
41 COSM6953061 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10994A>T p.D3665V 16:72787282-72787282 0
42 COSM6953714 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3431G>T p.C1144F 16:72889748-72889748 0
43 COSM6969956 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.527G>T p.G176V 16:72959619-72959619 0
44 COSM4062722 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2486T>C p.M829T 16:72957660-72957660 0
45 COSM6939807 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 0
46 COSM6956103 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2437A>T p.T813S 16:72957709-72957709 0
47 COSM6826441 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 0
48 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 2:97737758-97737758 0
49 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 17:1364977-1364977 0
50 COSM48846 YES1 lung,NS,carcinoma,adenocarcinoma c.473G>T p.W158L 18:746049-746049 0

Expression for Bronchiolo-Alveolar Adenocarcinoma

Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.

Pathways for Bronchiolo-Alveolar Adenocarcinoma

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pituitary gland development GO:0021983 9.37 CDH1 NKX2-1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.32 KRAS NKX2-1
3 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC4 MUC6
4 cerebral cortex cell migration GO:0021795 9.16 EGFR NKX2-1
5 pattern specification process GO:0007389 9.13 ASPH CDX2 NKX2-1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.8 KRAS MUC4 MUC6

Sources for Bronchiolo-Alveolar Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....